Answers are grounded in this paper and cite their sources.
Literature review evaluates minocycline's potential in neuroprotection for spinal cord injury, suggesting further research is needed.
Spinal cord injury (SCI) could be classified into traumatic and nontraumatic, according to its etiology. Traumatic SCI results from dangerous mechanism of injury and is frequently found concomitantly with traumatic brain injury patients. SCI is mostly associated with significant patient morbidity and mortality. Minocycline is a second-generation, tetracycline-class antibiotic that is feasible to find. Minocycline could be used for SCI with the mechanism of halting SCI neuroinflammation and progression. Hereby, I present a literature review to evaluate minocycline usage as a neuroprotector from inflammation in SCI patients. Literature searching was performed with keywords of minocycline and SCI; then, literature was critically appraised according to validity, importance, and applicability. Afterward, I found 15 appropriate preclinical and clinical studies that could be analyzed further in making this literature review. Minocycline, the tetracycline antibiotic subclass, has been used widely with minimal adverse effects, and good bioavailability could halt neuroinflammation through numerous pathways. The preclinical study showed that minocycline could improve animal SCI outcomes, and some clinical trials had shown its efficacy in treating SCI. Hence, I conclude that minocycline could be used as a supplementary therapy in any grade of SCI patient with the mechanism of halting neuroinflammation and stopping disease progression so that patient length of stay and morbidity could be minimized. Several clinical trials could be made to ensure minocycline efficacy for SCI treatment through local or systemic pathways based on its neuroprotective mechanism.
No takes yet. Share an insight, caveat, or question.
Kevin Tjandra (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: